Baker Bros. Advisors LP
Annual return '25
+24.0%
SPY '25
+17.7%
Alpha
+6.3ptsvs SPY
Invested
$17.4B
Holdings
84
Trades YTD
0
Performance · Fund vs SPY
Cumulative return · quarterly snapshotsCoverage 100%. 4 quarters of 2025 measured against SPY adj-close benchmark.
Top holdings · current snapshot
Source: 13F-HR01
$INCY
Incyte Corporation
Q1 2026: New position (2.4k shares)
16.6%
02
$ONC
BeOne Medicines Ltd.
Q1 2026: New position (1.9k shares)
15.0%
03
$INSM
Insmed Incorporated
Q1 2026: New position (19.7k shares)
7.0%
04
$MDGL
Madrigal Pharmaceuticals, Inc.
Q3 2025: Increased +8.4% (1.98M → 2.14M shares)
6.4%
05
$ACAD
ACADIA Pharmaceuticals Inc.
Q4 2024: New position (42.88M shares)
5.5%
06
$RVMD
Revolution Medicines, Inc.
Q1 2026: New position (1.8k shares)
5.3%
07
$CELC
Celcuity Inc.
Q3 2025: Increased +45.2% (5.45M → 7.92M shares)
5.2%
08
$KOD
Kodiak Sciences Inc.
Q4 2024: New position (17.31M shares)
4.4%
09
$KYMR
Kymera Therapeutics, Inc.
Q2 2025: Increased +10.9% (6.00M → 6.65M shares)
4.1%
10
$SMMT
Summit Therapeutics Inc.
Q1 2026: New position (69.6k shares)
4.0%
Recent trades · Last 90 days
No Form 4 / 13D / 13G trade events on file in the recent window. 13F filers report position snapshots quarterly rather than per-trade events, so this section is most useful for managers who also file Form 4 or 13D/G.
Convergence · Pattern Engine ships in v1.1
30-day windowIn development
Convergence participation lands with the Pattern Engine.
Once the Pattern Engine ships, this section will list every active convergence event this fund is named in — with the other named funds, the Congress members on the same name, and combined position size.
Source data: SEC EDGAR · 13F-HR filings · Performance through 2025-12-31 · Last refreshed 08:10 UTC.